{"classes":[{"categories":[{"measurements":[{"comment":"Mean and standard deviation were not estimable as no participant had detectable ADC at the pre-dose collection time point.","groupId":"OG000","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"title":"Cycle 1 - Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6782.22537","value":"32278.6310"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"title":"Cycle 1 - End of infusion (30 min)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3262.42585","value":"8017.2624"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"title":"Cycle 1 - Day 3 (48 hr)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1795.74382","value":"4703.5579"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"title":"Cycle 1 - Day 5 (96 hr)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"151.95902","value":"364.0768"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"title":"Cycle 2 - Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8062.68391","value":"31953.2729"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"title":"Cycle 2 - End of infusion (30 min)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3432.10921","value":"8944.7727"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"title":"Cycle 2 - Day 3 (48 hr)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"626.08923","value":"2674.7550"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"title":"Cycle 2 - Day 8 (168 hr)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"181.81833","value":"558.8526"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"title":"Cycle 3 - Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"361.75958","value":"1044.3557"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"title":"Cycle 4 - 15 to 21 Days Postdose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"247.80106","value":"617.9578"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"title":"Cycle 5 - Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"178.29961","value":"623.6881"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"title":"Cycle 6 - Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"412.67066","value":"1052.5095"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"title":"Cycle 6 - 15 to 21 Days Postdose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"198.78143","value":"660.0101"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"title":"Cycle 7 - Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"364.72862","value":"1091.6060"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"title":"Cycle 8 - 15 to 21 Days Postdose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"386.93255","value":"1071.2758"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"title":"Last - 15 to 21 Days Postdose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"description":"Antibody-Drug Conjugates (ADCs) are targeted cancer therapies that combine a monoclonal antibody with a cytotoxic drug to selectively deliver treatment to cancer cells while minimizing damage to healthy cells.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received brentuximab vedotin 1.8 mg/kg, IV infusion, within 1 hour of completing treatment with other IV agents, i.e., cyclophosphamide 750 mg/m\\^2 and doxorubicin 50 mg/m\\^2, on Day 1 of each 21-day cycle, and prednisone tablets, 100 mg daily, orally, on Days 1 through 5, for up to 8 cycles (6 months) or until PD, unacceptable toxicity, whichever occurred first.","id":"OG000","title":"Brentuximab Vedotin + CHP"}],"paramType":"MEAN","populationDescription":"The pharmacokinetic analysis set comprised of all participants who are in the FAS with at least 1 pharmacokinetic parameter. Here, \"number analyzed\" are the number of participants with data available for analysis at specified time-point.","reportingStatus":"POSTED","timeFrame":"Cycle 1:Predose on Day1 and at 30minutes (min),48and 96hours postdose;Cycle 2:Predose on Day1 and at 30min,48 and 168hours postdose;Predose on Day1 of Cycles3,5,6,7;Anytime once on Days15,21 of Cycles4,6,8;30 days post-last dose; each cycle=21days","title":"Serum Antibody-Drug Conjugate (ADC) Concentration","type":"SECONDARY","unitOfMeasure":"nanograms per milliliter (ng/mL)"}